GOG

Uterine Corpus Committee

Gynecologic Oncology Group

GOG0233/ACRIN 6671: Preoperative FDG-PET/CT to Detect Lymph Node Metastasis



Activated 9/24/07 **Revised** 6/9/08, 9/9/08, 11/12/08, 6/1/09, 11/16/09, 6/27/11, 7/2/12 **Closed** 12/3/12

Gynecologic Oncology Group

Endometrial: Stage I/II Adjuvant



- 3/23/2009 – 2/4/2013 Completed
- Endorsed by RTOG
- 562 accrued

GOG Gynecologic Oncology Group

Endometrial: Stage III/IV



- 6/29/2009
- Endorsed by RTOG
- 676/804 accrued

GOG Gynecologic Oncology Group

Pelvic Recurrence

- 2/25/2008
- Endorsed by RTOG
- 72/154 accrued



Institution IMRT Credentialing is required when IMRT is to be used before registering any patient on this trial. A Knowledge Assessment for this study must be completed by the treating radiation oncologist before registering patients on this trial.

For patients with tumors involving the distal vagina and clinically negative groins, the bilateral inguino-femoral lymph node regions should be treated to 4500 cGy.

3-D conformal or IMRT boost is allowed for patients who are not candidates for brachytherapy.

Carcinosarcoma



- 8/17/2009
- 581/603 accrued

GOG Gynecologic Oncology Group

Leiomyosarcoma: Stage I



Leiomyosarcoma: Measurable

- 11/9/2009 – 4/29/2013
- 107/130 accrued
- Closed



* All patients will receive GCSF on day 9 of each cycle.
Patients with a history of prior pelvic RT receive lower doses of the gemcitabine and docetaxel: gemcitabine 675 mg/m² IV over 70-90 minutes Days 1 and 8 plus docetaxel 60 mg/m² IV Day 8.

GOG Gynecologic Oncology Group

EORTC 62113-55115 / GOG UC1306
High Grade Undifferentiated Uterine Sarcoma



International Rare Cancers Initiative

GTN: Second Curettage



- 10/9/2007 – 2/25/2013
- 64/66 accrued
- Completed

LOW-RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA



6/18/2012
9/381 accrued
GCIG collaboration

Gynecologic Oncology Group